Skip to content

UCSF PANC Cyst Registry

Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04291651
Acronym
UCSF PCR
Enrollment
4000
Registered
2020-03-02
Start date
2019-10-08
Completion date
2030-01-01
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraductal Papillary Mucinous Neoplasm, Mucinous Cyst, Pancreatic Cancer, Pancreatic Cyst, Pancreatic Diseases, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatic Neoplasms

Keywords

Pancreatic Cyst, Pancreatic Cystic Lesion, Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, Serous Cystadenoma, Mucinous Cystic Neoplasm, Cancer Epidemiology, Early Detection Research

Brief summary

Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.

Detailed description

This study develops a large, prospectively managed, electronic, patient-directed pancreatic cyst registry based at UCSF. The UCSF Pancreatic Cystic Lesions Registry (PANC Cyst) will facilitate work to improve clinical care and understanding of pancreatic cysts by prospective follow-up of patients with cystic lesions, especially the diagnostically challenging small cysts, to identify factors related to cyst formation and progression to malignancy. Longitudinal data capture that includes clinical outcomes will also enable us to more precisely define anatomic, radiographic and biomarker information that can be used to differentiate populations of patients for whom surgery is indicated, surveillance is warranted, or no further evaluation is necessary.

Interventions

OTHERSurvey

There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include * Adults ≥ 30 years of age * Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status, * No history of pancreatic cancer, * Can speak and read English, * Have access to a computer or mobile device (\ 95% of U.S. population); and * Are able to complete an electronic informed consent.

Exclusion criteria

* Patients who don't speak English, * Don't have access to a computer or mobile device; or * Patients who have a cancer diagnosis.

Design outcomes

Primary

MeasureTime frameDescription
Cancer1-10 yearsWhile not the primary outcome measure, the development of cancer from a pancreatic cyst is a critically important study endpoint, which the investigators do not expect to be frequent occurrence.
Indolency1-10 yearsIf a patient with a pancreatic cyst experiences no or minimal change in size, and no development of worrisome or high-risk stigmata (Tanaka 2017), this will be considered to be an indolent lesion. Most patients will fall under this category.

Countries

United States

Contacts

Primary ContactCharysa Santos, BS
Charysa.Santos@ucsf.edu415-514-6914
Backup ContactKimberly S Kirkwood, MD
kim.kirkwood@ucsf.edu415-502-5577

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026